<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unique aspects of gastrointestinal disease in patients on dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unique aspects of gastrointestinal disease in patients on dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unique aspects of gastrointestinal disease in patients on dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Megha Salani, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence S Friedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gastrointestinal (GI) symptoms are reported in up to 80 percent of patients on dialysis [<a href="#rid1">1-3</a>]. This topic reviews GI disorders that occur with a higher prevalence or have clinical features that are unique to patients on dialysis. We also discuss management considerations that are specific to GI diseases in patients on dialysis.</p><p class="headingAnchor" id="H777147730"><span class="h1">UPPER AND LOWER GI TRACT</span></p><p class="headingAnchor" id="H670611038"><span class="h2">Angiodysplasia</span><span class="headingEndMark"> — </span>Angiodysplasias are the most common vascular anomalies encountered in patients with end-stage kidney disease (ESKD) and can occur in the upper and lower GI tract. They are usually multiple. While their presentation and management are in most respects similar to those of the non-ESKD population, patients with ESKD and chronic GI bleeding may benefit from estrogen therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Angiodysplasias account for approximately 20 and 30 percent of episodes of upper and lower GI bleeding, respectively, and for approximately one-half of recurrent episodes of upper GI bleeding in patients with ESKD [<a href="#rid4">4</a>]. It is unclear if the prevalence of angiodysplasia is higher among patients with ESKD as compared with the general population or if angiodysplastic lesions are detected more frequently in patients on hemodialysis due to exposure to anticoagulants and uremia-induced platelet dysfunction. (See  <a class="medical medical_review" href="/d/html/2557.html" rel="external">"Angiodysplasia of the gastrointestinal tract"</a> and  <a class="medical medical_review" href="/d/html/2557.html" rel="external">"Angiodysplasia of the gastrointestinal tract", section on 'End-stage kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and diagnosis </strong>– Patients usually present with chronic GI bleeding, although severe acute bleeding may also occur. Angiodysplastic lesions may also be found incidentally during endoscopic evaluation performed for other indications. The clinical presentation and diagnosis of angiodysplasia of the GI tract are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2557.html" rel="external">"Angiodysplasia of the gastrointestinal tract", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/2557.html" rel="external">"Angiodysplasia of the gastrointestinal tract", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Patients on dialysis with chronic GI bleeding may benefit from administration of conjugated estrogens. Small case series have suggested that estrogens may prevent recurrent bleeding from angiodysplasia and reduce transfusion requirements [<a href="#rid5">5,6</a>]. The management of GI bleeding in patients on dialysis is otherwise similar to that for patients not on dialysis and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction"</a>.)</p><p></p><p class="headingAnchor" id="H1082414879"><span class="h2">Endoscopy and peritoneal dialysis</span><span class="headingEndMark"> — </span>In patients on peritoneal dialysis, the abdomen should be drained before colonoscopy and upper endoscopy. In addition, we give prophylactic antibiotics to prevent peritonitis. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1867.html" rel="external">"Risk factors and prevention of peritonitis in peritoneal dialysis", section on 'Colonoscopy and upper endoscopy'</a>.)</p><p class="headingAnchor" id="H1670291988"><span class="h1">ESOPHAGUS AND STOMACH</span></p><p class="headingAnchor" id="H3958424071"><span class="h2">Peptic ulcer disease</span><span class="headingEndMark"> — </span>Peptic ulcer disease (PUD) is a common cause of GI bleeding in patients with ESKD. While the management of PUD in patients on dialysis is similar to that in the general population, the risk of rebleeding is higher in patients with ESKD [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4145135415"><span class="h2">Esophageal varices</span><span class="headingEndMark"> — </span>Patients on hemodialysis can rarely develop varices in the upper esophagus. These "downhill" esophageal varices, named after their downward direction of blood flow, result from superior vena cava (SVC) obstruction due to upper-extremity hemodialysis access [<a href="#rid8">8-10</a>]. Patients may be asymptomatic and discovered incidentally or present with upper GI bleeding. Definitive management involves treatment of the underlying SVC obstruction. However, in patients with severe upper GI bleeding, endoscopic therapy with variceal band ligation or sclerotherapy at the proximal end of the varix to temporize bleeding may be required prior to definitive treatment. (See  <a class="medical medical_review" href="/d/html/15223.html" rel="external">"Overview of iliocaval venous obstruction"</a> and  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a> and  <a class="medical medical_review" href="/d/html/1913.html" rel="external">"Central vein obstruction associated with upper extremity hemodialysis access"</a>.)</p><p class="headingAnchor" id="H851068748"><span class="h2">Gastroesophageal reflux</span><span class="headingEndMark"> — </span>Patients on peritoneal dialysis have a higher incidence of symptomatic gastroesophageal reflux disease compared with patients on hemodialysis [<a href="#rid11">11-14</a>]. This higher incidence is due in part to increased intra-abdominal pressure from the presence of the dialysate in the peritoneal cavity, which may be further exacerbated by rapid accumulation of ultrafiltrate. In addition, most patients perform peritoneal dialysis while supine, which can contribute to reflux. This is often a challenging issue to resolve. Decreasing the fill volumes and lowering ultrafiltration goals may mitigate the rise in intra-abdominal pressure, but it would be at the cost of peritoneal dialysis adequacy.</p><p class="headingAnchor" id="H980967562"><span class="h2">Gastroparesis</span><span class="headingEndMark"> — </span>Patients with ESKD are more likely to have gastroparesis; symptoms overlap with those of uremia. Typically, dialysis is optimized prior to an extensive work-up and management of gastroparesis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The frequency of gastroparesis (delayed gastric emptying) in ESKD is higher as compared with the general population, possibly due to a higher frequency of diabetes mellitus and the use of medications that can affect gastric emptying [<a href="#rid3">3,15-17</a>]. In patients on peritoneal dialysis, mechanical or neurogenic mechanisms triggered by the presence of intra-abdominal fluid have been implicated in delayed gastric emptying. Slower gastric motility with dextrose-based solutions compared with icodextrin-based solutions suggests a contribution from the caloric content of dialysate in addition to the fill volume [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/1890.html" rel="external">"Noninfectious complications of continuous peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> <strong>presentation</strong> – Undiagnosed gastroparesis is an important cause of malnutrition in patients with ESKD [<a href="#rid19">19</a>]. Similar to patients not on dialysis, patients with ESKD and gastroparesis can present with nausea, vomiting, abdominal pain, early satiety, postprandial fullness, bloating, and, in severe cases, weight loss. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Because symptoms of gastroparesis, particularly early satiety, nausea, and vomiting, are similar to those of uremia, the dialysis prescription and delivered dialysis dose should be assessed prior to performing an extensive evaluation for gastroparesis. In addition, all medications should be carefully reviewed, and culprit medications discontinued, when possible. As an example, iron supplements frequently cause abdominal pain. Phosphate binders, alkali replacement in the form of sodium citrate or <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, and some antihypertensive medications (eg, calcium channel blockers, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>) may cause nausea. The diagnostic evaluation for gastroparesis is the same as in the nondialysis population and is discussed separately. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/1866.html" rel="external">"Indications for initiation of dialysis in chronic kidney disease", section on 'Specific signs and symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of gastroparesis is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p></p><p class="headingAnchor" id="H2671891825"><span class="h1">SMALL INTESTINE AND COLON</span></p><p class="headingAnchor" id="H23"><span class="h2">Intestinal ischemia</span><span class="headingEndMark"> — </span>Mesenteric and colonic ischemia in the setting of hemodialysis is typically nonocclusive [<a href="#rid20">20</a>]. Risk factors in patients with end-stage kidney disease (ESKD) include older age, peripheral vascular disease, hypotension during hemodialysis, and prolonged hypotension following a hemodialysis session. (See  <a class="medical medical_review" href="/d/html/91221.html" rel="external">"Nonocclusive mesenteric ischemia", section on 'Epidemiology and risk factors'</a>.)</p><p>Patients with nonocclusive mesenteric ischemia may be asymptomatic or present with mild abdominal pain, bloating, nausea, or vomiting [<a href="#rid21">21-23</a>]. Patients with acute colonic ischemia usually present with the rapid onset of mild cramping abdominal pain. Rectal bleeding or bloody diarrhea usually develops within 24 hours. Patients on dialysis have more severe ischemic colitis and right-sided colitis as compared with patients not on dialysis [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/91221.html" rel="external">"Nonocclusive mesenteric ischemia", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/2564.html" rel="external">"Colonic ischemia", section on 'Acute colonic ischemia'</a>.)</p><p>Among patients undergoing peritoneal dialysis, the symptoms of ischemia may mimic those of peritonitis, resulting in a delay in diagnosis and a high mortality rate [<a href="#rid25">25,26</a>]. The diagnostic evaluation and treatment of patients with ischemic colitis and mesenteric ischemia are similar to those for the nondialysis population and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2564.html" rel="external">"Colonic ischemia", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Constipation/fecal impaction</span><span class="headingEndMark"> — </span>Constipation and fecal impaction can occur secondary to the use of phosphate binders, analgesics, and iron in patients on dialysis. We avoid <a class="drug drug_general" data-topicid="10261" href="/d/drug information/10261.html" rel="external">sevelamer</a> and <a class="drug drug_general" data-topicid="10219" href="/d/drug information/10219.html" rel="external">lanthanum carbonate</a> phosphate binders in patients with a history of fecal impaction or bowel obstruction [<a href="#rid27">27,28</a>]. Patients on dialysis with a history of constipation should avoid aluminum-containing antacids and analgesics. In such patients, these medications can increase the risk of recurrent fecal impaction and aluminum toxicity. (See  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease", section on 'Aluminum-containing phosphate binders and antacids'</a>.)</p><p>The management of constipation in patients on dialysis is similar to that for the general population, with the exception that phosphate-containing laxatives are contraindicated in patients with kidney failure. Magnesium-containing antacids, such as milk of magnesia, should only be used if monitoring of the blood magnesium concentration is feasible. <a class="drug drug_general" data-topicid="9543" href="/d/drug information/9543.html" rel="external">Lactulose</a> may be the preferred laxative for chronic use in patients on peritoneal dialysis [<a href="#rid29">29</a>]. The management of fecal impaction and constipation are discussed separately. (See  <a class="medical medical_review" href="/d/html/16133.html" rel="external">"Constipation in the older adult", section on 'Management'</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Acute diverticulitis</span><span class="headingEndMark"> — </span>The frequency of diverticulosis is not increased in patients on dialysis, except for those with underlying polycystic kidney disease [<a href="#rid30">30-32</a>]. However, the risk of acute diverticulitis may be increased in patients with ESKD [<a href="#rid33">33</a>]. The clinical presentation, diagnosis, and management of acute diverticulitis are the same as for patients without ESKD. However, operative resection for diverticulitis is associated with a high mortality rate in older patients with ESKD [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/1679.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Extrarenal manifestations"</a> and  <a class="medical medical_review" href="/d/html/2633.html" rel="external">"Clinical manifestations and diagnosis of acute colonic diverticulitis in adults"</a> and  <a class="medical medical_review" href="/d/html/1380.html" rel="external">"Acute colonic diverticulitis: Medical management"</a>.)</p><p>The incidence of fecal peritonitis is increased in all adult patients undergoing chronic peritoneal dialysis. Recurrent diverticulitis is a relative contraindication to peritoneal dialysis. However, if peritoneal dialysis is a preferred option for other reasons (ie, distance to hemodialysis center, poor vascular access, severe heart failure), then the risk/benefit discussion should include a discussion of fecal peritonitis. (See  <a class="medical medical_review" href="/d/html/1844.html" rel="external">"Dialysis modality and patient outcome", section on 'Selection of dialysis modality'</a> and  <a class="medical medical_review" href="/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis", section on 'Peritoneal dialysis'</a>.)</p><p>A history of acute diverticulitis is an important consideration in transplant candidates since colonic perforation due to diverticulitis is associated with a high mortality rate [<a href="#rid31">31</a>]. In patients with indications for surgery (eg, extensive and/or recurrent symptomatic diverticular disease), resection is often performed electively prior to transplant. </p><p class="headingAnchor" id="H4037757573"><span class="h2">Rare gastrointestinal diseases</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis-related gastrointestinal amyloidosis </strong>– Dialysis-related amyloidosis is rare and is related to the length of time on dialysis [<a href="#rid35">35</a>]. GI manifestations include GI bleeding, mesenteric ischemia, bowel perforation, and colonic pseudo-obstruction. (See  <a class="medical medical_review" href="/d/html/1983.html" rel="external">"Dialysis-related amyloidosis"</a> and  <a class="medical medical_review" href="/d/html/2642.html" rel="external">"Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intestinal necrosis </strong>– <a class="drug drug_general" data-topicid="9936" href="/d/drug information/9936.html" rel="external">Sodium polystyrene sulfonate</a> (SPS), a cation exchange resin commonly used for the treatment of hyperkalemia in patients with kidney failure, has been associated with intestinal necrosis, ulceration, perforation, and mesenteric vascular thrombosis [<a href="#rid36">36</a>]. SPS-associated intestinal necrosis is discussed in detail separately. This adverse effect does not appear to be associated with the newer intestinal potassium binders, <a class="drug drug_general" data-topicid="104961" href="/d/drug information/104961.html" rel="external">patiromer</a> and sodium-zirconium cyclosilicate. (See  <a class="medical medical_review" href="/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults", section on 'Do not use sodium polystyrene sulfonate (SPS) or other resins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spontaneous colonic perforation </strong>– Among patients with ESKD, spontaneous colonic perforation can occur in association with aluminum-containing antacids, <a class="drug drug_general" data-topicid="9180" href="/d/drug information/9180.html" rel="external">barium</a> contrast, fecal impaction, or dehydration [<a href="#rid37">37,38</a>]. However, the etiology is unknown in many patients on dialysis. The diagnosis must be considered in patients presenting with acute abdominal pain. (See  <a class="medical medical_review" href="/d/html/15075.html" rel="external">"Overview of gastrointestinal tract perforation", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uremic colitis </strong>– Prior to the availability of maintenance dialysis, autopsy studies of patients with untreated uremia revealed extensive colonic ulcerations and pseudomembranes [<a href="#rid37">37,39</a>]. These findings, which were termed uremic colitis, are now rarely observed among patients on hemodialysis.</p><p></p><p class="headingAnchor" id="H597374297"><span class="h2">Bowel preparation for lower gastrointestinal endoscopy</span><span class="headingEndMark"> — </span>Bowel preparation with hyperosmotic laxative regimens (eg, <a class="drug drug_general" data-topicid="10269" href="/d/drug information/10269.html" rel="external">sodium phosphate</a> or <a class="drug drug_general" data-topicid="9580" href="/d/drug information/9580.html" rel="external">magnesium citrate</a>) should be avoided in patients on dialysis. Such preparations can raise serum levels of phosphate or magnesium and provoke further loss of residual kidney function. Recommended preparations in patients with kidney function impairment (eg, polyethylene glycol-electrolyte lavage solution) are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2665.html" rel="external">"Bowel preparation before colonoscopy in adults", section on 'Patients with heart failure, renal insufficiency, end-stage liver disease, or electrolyte imbalances'</a>.)</p><p class="headingAnchor" id="H197282955"><span class="h1">PANCREAS</span></p><p class="headingAnchor" id="H841129578"><span class="h2">Acute pancreatitis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – The risk of acute pancreatitis is higher among patients on dialysis as compared with the general population [<a href="#rid40">40-46</a>]. In a retrospective cohort study of 67,078 patients with end-stage kidney disease (ESKD), the cumulative incidence of acute pancreatitis at one, three, five, seven, and nine years after initiating dialysis was 0.6, 1.7, 2.6, 3.4, and 4 percent, respectively [<a href="#rid40">40</a>]. The risk of acute pancreatitis was higher among patients undergoing peritoneal dialysis as compared with hemodialysis (5.11 and 5.86 per 1000 person-years).</p><p></p><p class="bulletIndent1">The etiology of acute pancreatitis in patients on dialysis is similar to that for patients not on dialysis. However, some risk factors may be more prevalent in patients on dialysis (eg, hypercalcemia due to hyperparathyroidism) [<a href="#rid41">41,44,47-50</a>] (see  <a class="medical medical_review" href="/d/html/5640.html" rel="external">"Etiology of acute pancreatitis"</a>). The risk of acute pancreatitis may be increased among patients on peritoneal dialysis by chronic exposure to specific dialysate solutions, such as high dextrose-containing dialysate (ie, 4.25 percent) [<a href="#rid42">42-44</a>]. By contrast, <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> was associated with a lower risk of acute pancreatitis in one study [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/1905.html" rel="external">"Peritoneal dialysis solutions", section on 'Constituents'</a>.)</p><p></p><p class="bulletIndent1">Although dyslipidemia is highly prevalent in patients with kidney disease, triglyceride concentrations that are high enough to cause acute pancreatitis (&gt;1000 mg/dL) are rare. (See  <a class="medical medical_review" href="/d/html/5640.html" rel="external">"Etiology of acute pancreatitis"</a> and  <a class="medical medical_review" href="/d/html/5655.html" rel="external">"Hypertriglyceridemia-induced acute pancreatitis"</a> and  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Dyslipidemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> <strong>presentation</strong> <strong>and</strong> <strong>diagnosis</strong> – The symptoms of acute pancreatitis in patients on hemodialysis are similar to those in patients without kidney failure. Serum concentrations of pancreatic amylase and lipase are elevated in patients with ESKD in the absence of acute pancreatitis [<a href="#rid46">46</a>]. However, the absolute values generally do not exceed three times the upper limit of normal. </p><p></p><p class="bulletIndent1">In patients on peritoneal dialysis, icodextrin-containing dialysate solutions interfere with the serum amylase assay, falsely lowering it [<a href="#rid52">52</a>]. For this reason, we use serum lipase rather than amylase for diagnosis of acute pancreatitis among such patients. It is also important to differentiate acute pancreatitis from microbial peritonitis in patients on peritoneal dialysis. The clinical presentation and diagnosis of acute pancreatitis and microbial peritonitis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1895.html" rel="external">"Serum enzymes in patients with kidney failure", section on 'Pancreatic enzymes'</a> and  <a class="medical medical_review" href="/d/html/5652.html" rel="external">"Clinical manifestations and diagnosis of acute pancreatitis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5643.html" rel="external">"Approach to the patient with elevated serum amylase or lipase"</a> and  <a class="medical medical_review" href="/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Fluid administration and volume status should be closely monitored, since patients with ESKD often do not tolerate the aggressive intravenous fluid regimens typically used for acute pancreatitis. </p><p></p><p class="bulletIndent1">For patients on hemodialysis with acute pancreatitis, we minimize heparin use during the dialysis procedure to reduce the risk of hemorrhagic pancreatitis.</p><p></p><p class="bulletIndent1">Peritoneal dialysis should not routinely be discontinued in all patients with acute pancreatitis and should only be halted if there is a high suspicion that the dialysate itself is the culprit. We suspect the dialysate is a cause of acute pancreatitis if the dialysis prescription had been recently changed preceding the onset of symptoms, particularly if the new prescription includes exchanges with high dextrose-containing dialysate (ie, 4.25 percent dextrose) or <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>. In such patients, we discontinue the 4.25 percent dextrose or icodextrin dialysate and continue peritoneal dialysis using a lower concentration of dextrose (ie, 1.25 or 2.5 percent dextrose). Peritoneal lavage can be helpful in removing inflammatory mediators. In addition, studies suggest that discontinuation of peritoneal dialysis does not improve outcomes in patients with acute pancreatitis [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Some reports suggest that patients on dialysis with acute pancreatitis have a worse prognosis as compared with those without kidney disease [<a href="#rid42">42,47,53</a>]. </p><p></p><p class="bulletIndent1">As an example, in a study that compared outcomes among over 26,000 patients with acute pancreatitis, those receiving dialysis had a higher in-hospital mortality compared with those without chronic kidney disease (adjusted odds ratio 2.72, 95% CI 2.22-3.33) [<a href="#rid54">54</a>]. However, morbidity and mortality due to acute pancreatitis appear to be similar in patients undergoing hemodialysis or peritoneal dialysis [<a href="#rid55">55</a>].</p><p></p><p class="headingAnchor" id="H3460129584"><span class="h2">Exocrine pancreatic insufficiency/chronic pancreatitis</span><span class="headingEndMark"> — </span>ESKD has been implicated as a risk for chronic pancreatitis, possibly due to direct uremic toxicity. It is unclear if the prevalence of chronic pancreatitis is increased in patients with ESKD; however, exocrine pancreatic insufficiency appears to be frequent in such patients. In one study that included 50 patients on hemodialysis who had no history of acute or chronic pancreatitis, mild to moderate exocrine pancreatic insufficiency was reported in 10 percent [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/4779.html" rel="external">"Exocrine pancreatic insufficiency"</a>.)</p><p class="headingAnchor" id="H229973471"><span class="h1">LIVER</span></p><p class="headingAnchor" id="H30"><span class="h2">Hemodialysis-associated ascites</span><span class="headingEndMark"> — </span>Patients on maintenance hemodialysis can develop ascites in the absence of any other clear underlying cause.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– The incidence of hemodialysis-associated ascites is not well established but appears to have declined due to improvement in hemodialysis technology, better control of volume overload, enhanced dialysis dose, and better nutrition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and risk factors</strong> – Although the pathogenesis of hemodialysis-associated ascites is unclear, possible mechanisms include chronic volume overload with hepatic congestion and increased hepatic vein hydrostatic pressure, changes in the permeability of the peritoneal membrane in patients previously on peritoneal dialysis, and impaired lymphatic peritoneal resorption. Other contributing factors include hypoalbuminemia, congestive heart failure, and hyperparathyroidism [<a href="#rid57">57-61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and diagnosis</strong> – Clinical features include abdominal distension, cachexia, and symptoms of volume overload (eg, weight gain, shortness of breath, early satiety, and dyspnea) and malnutrition.</p><p></p><p class="bulletIndent1">Ascitic fluid in patients with hemodialysis-associated ascites is clear and has a high protein content (3 to 6 g/dL) with a low serum ascites albumin gradient (&lt;1.1) and neutrophil count. The diagnosis of hemodialysis-associated ascites is one of exclusion and requires an evaluation to rule out other causes of ascites. This evaluation is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1261.html" rel="external">"Evaluation of adults with ascites"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The initial management of hemodialysis-associated ascites includes volume control with salt and fluid restriction, aggressive fluid removal by ultrafiltration, intermittent paracentesis, and improved nutritional intake [<a href="#rid62">62</a>]. However, hypotension may be a limiting factor in some patients. (See  <a class="medical medical_review" href="/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy"</a>.)</p><p></p><p class="bulletIndent1">If these initial measures fail to provide substantial benefit, switching to continuous ambulatory peritoneal dialysis (CAPD) may reduce the severity of ascites and improve nutritional status. Limited data suggest that placement of a peritoneovenous shunt (Denver or LeVeen shunt) may result in an improvement in hemodynamic stability and nutritional status and a reduction of ascites [<a href="#rid63">63,64</a>]. However, major complications of peritoneovenous shunt include infections and malfunction. (See  <a class="medical medical_review" href="/d/html/2308.html" rel="external">"Hepatorenal syndrome", section on 'Peritoneovenous shunt'</a>.)</p><p></p><p class="bulletIndent1">Dialysis-associated ascites has a poor prognosis with a mortality rate of 45 percent within 15 months of diagnosis [<a href="#rid65">65,66</a>]. Kidney transplantation is the only definitive treatment, and complete resolution of ascites has been reported to occur within six weeks of transplantation in almost all patients [<a href="#rid67">67,68</a>]. However, not all transplant centers will perform transplantation in patients with recurrent ascites. (See  <a class="medical medical_review" href="/d/html/1258.html" rel="external">"Ascites in adults with cirrhosis: Diuretic-resistant ascites"</a>.)</p><p></p><p class="headingAnchor" id="H1664895228"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>The epidemiology, diagnosis, and treatment of hepatitis B virus and hepatitis C virus infection among patients on dialysis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1861.html" rel="external">"Hepatitis C virus infection in patients on maintenance dialysis"</a> and  <a class="medical medical_review" href="/d/html/1931.html" rel="external">"Hepatitis B virus and dialysis patients"</a> and  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>.)</p><p class="headingAnchor" id="H2327238859"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H835986386"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Gastrointestinal (GI) symptoms are reported in up to 80 percent of patients on dialysis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper and lower GI tract</strong> – GI angiodysplasias account for approximately 20 and 30 percent of episodes of upper and lower GI bleeding in patients with end-stage kidney disease (ESKD). (See <a class="local">'Angiodysplasia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophagus and stomach</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Esophageal varices</strong> – Patients on hemodialysis can develop varices in the upper esophagus from superior vena cava (SVC) obstruction due to upper-extremity hemodialysis access. Patients may be asymptomatic and discovered incidentally or present with upper GI bleeding. Definitive management involves treatment of the underlying SVC obstruction. However, in patients with severe upper GI bleeding, endoscopic therapy with variceal band ligation or sclerotherapy may be needed to temporize bleeding prior to definitive treatment. (See <a class="local">'Esophageal varices'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastroparesis </strong>– The prevalence of gastroparesis in ESKD is higher as compared with the general population, possibly due to a higher prevalence of diabetes mellitus and the use of medications that affect gastric emptying. Because symptoms of gastroparesis are similar to those of uremia, the dialysis prescription and delivered dialysis dose should be assessed prior to performing an extensive evaluation for gastroparesis. In addition, all medications should be carefully reviewed and culprit medications discontinued. (See <a class="local">'Gastroparesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small intestine and colon</strong>  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intestinal ischemia</strong> – Mesenteric and colonic ischemia in the setting of hemodialysis is typically nonocclusive and is frequently due to underlying hemodialysis-induced hypotension. Patients on dialysis have more severe ischemic colitis and right-sided colitis as compared with patients not on dialysis. Among patients undergoing peritoneal dialysis, the symptoms of ischemia may mimic those of peritonitis. (See <a class="local">'Intestinal ischemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Constipation and fecal impaction</strong> – Constipation and fecal impaction can occur secondary to the use of phosphate binders, analgesics, and iron. Magnesium and phosphate-containing laxatives are contraindicated in patients with ESKD. (See <a class="local">'Constipation/fecal impaction'</a> above and <a class="local">'Bowel preparation for lower gastrointestinal endoscopy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreas</strong> – Patients on dialysis have a higher risk of acute pancreatitis and a more severe clinical course. Risk factors for acute pancreatitis that are more prevalent in patients with ESKD include hypercalcemia due to hyperparathyroidism. In patients on peritoneal dialysis, risk may be increased by chronic local exposure to specific peritoneal dialysate solutions (eg, 4.25 percent dextrose and <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>). (See <a class="local">'Acute pancreatitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver</strong> – Patients on maintenance hemodialysis can develop ascites in the absence of any other clear underlying cause. The diagnosis of hemodialysis-associated ascites is one of exclusion and requires an evaluation to rule out other causes of ascites. The initial management includes volume control with salt and fluid restriction, aggressive fluid removal by ultrafiltration, intermittent paracentesis, and improved nutritional intake. If initial measures fail, options include switching to continuous ambulatory peritoneal dialysis (CAPD) and placement of a peritoneovenous shunt. Kidney transplantation is the only definitive treatment. (See <a class="local">'Hemodialysis-associated ascites'</a> above.)</p><p></p><p class="headingAnchor" id="H4059183177"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Yousri M Barri, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hammer J, Oesterreicher C, Hammer K, et al. Chronic gastrointestinal symptoms in hemodialysis patients. Wien Klin Wochenschr 1998; 110:287.</a></li><li><a class="nounderline abstract_t">Chong VH. Impact of duration of hemodialysis on gastrointestinal symptoms in patients with end stage renal failure. J Gastrointestin Liver Dis 2010; 19:462.</a></li><li><a class="nounderline abstract_t">Van Vlem B, Schoonjans R, Vanholder R, et al. Delayed gastric emptying in dyspeptic chronic hemodialysis patients. Am J Kidney Dis 2000; 36:962.</a></li><li><a class="nounderline abstract_t">Zuckerman GR, Cornette GL, Clouse RE, Harter HR. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 1985; 102:588.</a></li><li><a class="nounderline abstract_t">Bronner MH, Pate MB, Cunningham JT, Marsh WH. Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial. Ann Intern Med 1986; 105:371.</a></li><li><a class="nounderline abstract_t">Richardson JD, Lordon RE. Gastrointestinal bleeding caused by angiodysplasia: a difficult problem in patients with chronic renal failure receiving hemodialysis therapy. Am Surg 1993; 59:636.</a></li><li><a class="nounderline abstract_t">Cheung J, Yu A, LaBossiere J, et al. Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest Endosc 2010; 71:44.</a></li><li><a class="nounderline abstract_t">Blam ME, Kobrin S, Siegelman ES, Scotiniotis IA. "Downhill" esophageal varices as an iatrogenic complication of upper extremity hemodialysis access. Am J Gastroenterol 2002; 97:216.</a></li><li><a class="nounderline abstract_t">Chandra A, Tso R, Cynamon J, Miller G. Massive upper GI bleeding in a long-term hemodialysis patient. Chest 2005; 128:1868.</a></li><li><a class="nounderline abstract_t">Loudin M, Anderson S, Schlansky B. Bleeding 'downhill' esophageal varices associated with benign superior vena cava obstruction: case report and literature review. BMC Gastroenterol 2016; 16:134.</a></li><li><a class="nounderline abstract_t">Lee YC, Hung SY, Wang HH, et al. Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) 2015; 94:e1482.</a></li><li><a class="nounderline abstract_t">Dong R, Guo ZY, Ding JR, et al. Gastrointestinal symptoms: a comparison between patients undergoing peritoneal dialysis and hemodialysis. World J Gastroenterol 2014; 20:11370.</a></li><li><a class="nounderline abstract_t">Huang KW, Leu HB, Luo JC, et al. Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis. Dig Dis Sci 2014; 59:807.</a></li><li><a class="nounderline abstract_t">Strid H, Simrén M, Johansson AC, et al. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transplant 2002; 17:1434.</a></li><li><a class="nounderline abstract_t">Keshavarzian A, Iber FL. Gastrointestinal involvement in insulin-requiring diabetes mellitus. J Clin Gastroenterol 1987; 9:685.</a></li><li><a class="nounderline abstract_t">McNamee PT, Moore GW, McGeown MG, et al. Gastric emptying in chronic renal failure. Br Med J (Clin Res Ed) 1985; 291:310.</a></li><li><a class="nounderline abstract_t">Nassar Y, Richter S. Gastroparesis in Non-Diabetics: Associated Conditions and Possible Risk Factors. Gastroenterology Res 2018; 11:340.</a></li><li><a class="nounderline abstract_t">Van V, Schoonjans RS, Struijk DG, et al. Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 2002; 22:32.</a></li><li><a class="nounderline abstract_t">Ross EA, Koo LC. Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients. Am J Kidney Dis 1998; 31:62.</a></li><li><a class="nounderline abstract_t">Li SY, Chen YT, Chen TJ, et al. Mesenteric ischemia in patients with end-stage renal disease: a nationwide longitudinal study. Am J Nephrol 2012; 35:491.</a></li><li><a class="nounderline abstract_t">Bassilios N, Menoyo V, Berger A, et al. Mesenteric ischaemia in haemodialysis patients: a case/control study. Nephrol Dial Transplant 2003; 18:911.</a></li><li><a class="nounderline abstract_t">Dahlberg PJ, Kisken WA, Newcomer KL, Yutuc WR. Mesenteric ischemia in chronic dialysis patients. Am J Nephrol 1985; 5:327.</a></li><li><a class="nounderline abstract_t">Ori Y, Chagnac A, Schwartz A, et al. Non-occlusive mesenteric ischemia in chronically dialyzed patients: a disease with multiple risk factors. Nephron Clin Pract 2005; 101:c87.</a></li><li><a class="nounderline abstract_t">Flobert C, Cellier C, Berger A, et al. Right colonic involvement is associated with severe forms of ischemic colitis and occurs frequently in patients with chronic renal failure requiring hemodialysis. Am J Gastroenterol 2000; 95:195.</a></li><li><a class="nounderline abstract_t">Wellington JL, Rody K. Acute abdominal emergencies in patients on long-term ambulatory peritoneal dialysis. Can J Surg 1993; 36:522.</a></li><li><a class="nounderline abstract_t">Archodovassilis F, Lagoudiannakis EE, Tsekouras DK, et al. Nonocclusive mesenteric ischemia: a lethal complication in peritoneal dialysis patients. Perit Dial Int 2007; 27:136.</a></li><li><a class="nounderline abstract_t">Korzets A, Tsitman I, Lev N, et al. Lanthanum, constipation, bafflying X-rays and a perforated colonic diverticulum. Clin Kidney J 2012; 5:331.</a></li><li><a class="nounderline abstract_t">Yuste C, Mérida E, Hernández E, et al. Gastrointestinal complications induced by sevelamer crystals. Clin Kidney J 2017; 10:539.</a></li><li><a class="nounderline abstract_t">Pipili C, Polydorou A, Pantelias K, et al. Improvement of hepatic encephalopathy by application of peritoneal dialysis in a patient with non-end-stage renal disease. Perit Dial Int 2013; 33:213.</a></li><li><a class="nounderline abstract_t">Scheff RT, Zuckerman G, Harter H, et al. Diverticular disease in patients with chronic renal failure due to polycystic kidney disease. Ann Intern Med 1980; 92:202.</a></li><li><a class="nounderline abstract_t">Church JM, Fazio VW, Braun WE, et al. Perforation of the colon in renal homograft recipients. A report of 11 cases and a review of the literature. Ann Surg 1986; 203:69.</a></li><li><a class="nounderline abstract_t">Galbraith P, Bagg MN, Schabel SI, Rajagopalan PR. Diverticular complications of renal failure. Gastrointest Radiol 1990; 15:259.</a></li><li><a class="nounderline abstract_t">Chang SS, Huang N, Hu HY. Patients with end-stage renal disease were at an increased risk of hospitalization for acute diverticulitis. Medicine (Baltimore) 2016; 95:e4881.</a></li><li><a class="nounderline abstract_t">Moran-Atkin E, Stem M, Lidor AO. Surgery for diverticulitis is associated with high risk of in-hospital mortality and morbidity in older patients with end-stage renal disease. Surgery 2014; 156:361.</a></li><li><a class="nounderline abstract_t">Jimenez RE, Price DA, Pinkus GS, et al. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol 1998; 22:729.</a></li><li><a class="nounderline abstract_t">Noel JA, Bota SE, Petrcich W, et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. JAMA Intern Med 2019; 179:1025.</a></li><li><a class="nounderline abstract_t">Brown KM. Isolated ascending colon ulceration in a patient with chronic renal insufficiency. J Natl Med Assoc 1992; 84:185.</a></li><li><a class="nounderline abstract_t">Bischel MD, Reese T, Engel J. Spontaneous perforation of the colon in a hemodialysis patient. Am J Gastroenterol 1980; 74:182.</a></li><li><a class="nounderline abstract_t">Milito G, Taccone-Gallucci M, Brancaleone C, et al. The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int Suppl 1985; 17:S157.</a></li><li><a class="nounderline abstract_t">Chen HJ, Wang JJ, Tsay WI, et al. Epidemiology and outcome of acute pancreatitis in end-stage renal disease dialysis patients: a 10-year national cohort study. Nephrol Dial Transplant 2017.</a></li><li><a class="nounderline abstract_t">Padilla B, Pollak VE, Pesce A, et al. Pancreatitis in patients with end-stage renal disease. Medicine (Baltimore) 1994; 73:8.</a></li><li><a class="nounderline abstract_t">Rutsky EA, Robards M, Van Dyke JA, Rostand SG. Acute pancreatitis in patients with end-stage renal disease without transplantation. Arch Intern Med 1986; 146:1741.</a></li><li><a class="nounderline abstract_t">Caruana RJ, Wolfman NT, Karstaedt N, Wilson DJ. Pancreatitis: an important cause of abdominal symptoms in patients on peritoneal dialysis. Am J Kidney Dis 1986; 7:135.</a></li><li><a class="nounderline abstract_t">Bruno MJ, van Westerloo DJ, van Dorp WT, et al. Acute pancreatitis in peritoneal dialysis and haemodialysis: risk, clinical course, outcome, and possible aetiology. Gut 2000; 46:385.</a></li><li><a class="nounderline abstract_t">Lankisch PG, Weber-Dany B, Maisonneuve P, Lowenfels AB. Frequency and severity of acute pancreatitis in chronic dialysis patients. Nephrol Dial Transplant 2008; 23:1401.</a></li><li><a class="nounderline abstract_t">Barbara M, Tsen A, Rosenkranz L. Acute Pancreatitis in Chronic Dialysis Patients. Pancreas 2018; 47:946.</a></li><li><a class="nounderline abstract_t">Joglar FM, Saadé M. Outcome of pancreatitis in CAPD and HD patients. Perit Dial Int 1995; 15:264.</a></li><li><a class="nounderline abstract_t">Moreiras Plaza M, Rodríguez Goyanes G, Cuiña L, Alonso R. On the toxicity of valproic-acid. Clin Nephrol 1999; 51:187.</a></li><li><a class="nounderline abstract_t">Kishino T, Nakamura K, Mori H, et al. Acute pancreatitis during haemodialysis. Nephrol Dial Transplant 2005; 20:2012.</a></li><li><a class="nounderline abstract_t">Kheda MF, Szerlip HM. Two cases of iodixanol-induced pancreatitis. NDT Plus 2008; 1:296.</a></li><li><a class="nounderline abstract_t">Wang IK, Lai SW, Lai HC, et al. Risk of and Fatality from Acute Pancreatitis in Long-Term Hemodialysis and Peritoneal Dialysis Patients. Perit Dial Int 2018; 38:30.</a></li><li><a class="nounderline abstract_t">Schoenicke G, Grabensee B, Plum J. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 2002; 17:1988.</a></li><li><a class="nounderline abstract_t">Pannekeet MM, Krediet RT, Boeschoten EW, Arisz L. Acute pancreatitis during CAPD in The Netherlands. Nephrol Dial Transplant 1993; 8:1376.</a></li><li><a class="nounderline abstract_t">Kroner PT, Mareth K, Raimondo M, et al. Acute Pancreatitis in Advanced Chronic Kidney Disease and Kidney Transplant Recipients: Results of a US Nationwide Analysis. Mayo Clin Proc Innov Qual Outcomes 2019; 3:160.</a></li><li><a class="nounderline abstract_t">Quraishi ER, Goel S, Gupta M, et al. Acute pancreatitis in patients on chronic peritoneal dialysis: an increased risk? Am J Gastroenterol 2005; 100:2288.</a></li><li><a class="nounderline abstract_t">Griesche-Philippi J, Otto J, Schwörer H, et al. Exocrine pancreatic function in patients with end-stage renal disease. Clin Nephrol 2010; 74:457.</a></li><li><a class="nounderline abstract_t">Cintin C, Joffe P. Nephrogenic ascites. Case report and review of the literature. Scand J Urol Nephrol 1994; 28:311.</a></li><li><a class="nounderline abstract_t">Rodriguez HJ, Walls J, Slatopolsky E, Klahr S. Recurrent ascites following peritoneal dialysis. A new syndrome? Arch Intern Med 1974; 134:283.</a></li><li><a class="nounderline abstract_t">Hammond TC, Takiyyuddin MA. Nephrogenic ascites: a poorly understood syndrome. J Am Soc Nephrol 1994; 5:1173.</a></li><li><a class="nounderline abstract_t">Rubin J, Rust P, Brown P, et al. A comparison of peritoneal transport in patients with psoriasis and uremia. Nephron 1981; 29:185.</a></li><li><a class="nounderline abstract_t">Nasr EM, Joubran NI. Is nephrogenic ascites related to secondary hyperparathyroidism? Am J Kidney Dis 2001; 37:E16.</a></li><li><a class="nounderline abstract_t">Gunal AI, Karaca I, Celiker H, et al. Strict volume control in the treatment of nephrogenic ascites. Nephrol Dial Transplant 2002; 17:1248.</a></li><li><a class="nounderline abstract_t">Holm A, Rutsky EA, Aldrete JS. Short- and long-term effectiveness, morbidity, and mortality of peritoneovenous shunt inserted to treat massive refractory ascites of nephrogenic origin analysis of 14 cases. Am Surg 1989; 55:645.</a></li><li><a class="nounderline abstract_t">Morgan AG, Sivapragasam S, Fletcher P, Terry SI. Hemodynamic improvement after peritoneovenous shunting in nephrogenic ascites. South Med J 1982; 75:373.</a></li><li><a class="nounderline abstract_t">Glück Z, Nolph KD. Ascites associated with end-stage renal disease. Am J Kidney Dis 1987; 10:9.</a></li><li><a class="nounderline abstract_t">Feingold LN, Gutman RA, Walsh FX, Gunnells JC. Control of cachexia and ascites in hemodialysis patients by binephrectomy. Arch Intern Med 1974; 134:989.</a></li><li><a class="nounderline abstract_t">Popli S, Chen WT, Nakamoto S, et al. Hemodialysis ascites in anephric patients. Clin Nephrol 1981; 15:203.</a></li><li><a class="nounderline abstract_t">Melero M, Rodriguez M, Araque A, et al. Idiopathic dialysis ascites in the nineties: resolution after renal transplantation. Am J Kidney Dis 1995; 26:668.</a></li></ol></div><div id="topicVersionRevision">Topic 1897 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9615960" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic gastrointestinal symptoms in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21188344" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of duration of hemodialysis on gastrointestinal symptoms in patients with end stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054352" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Delayed gastric emptying in dyspeptic chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872616" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Upper gastrointestinal bleeding in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3488703" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214961" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gastrointestinal bleeding caused by angiodysplasia: a difficult problem in patients with chronic renal failure receiving hemodialysis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19595311" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11808963" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : "Downhill" esophageal varices as an iatrogenic complication of upper extremity hemodialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162797" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Massive upper GI bleeding in a long-term hemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27776486" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bleeding 'downhill' esophageal varices associated with benign superior vena cava obstruction: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26356710" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170224" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gastrointestinal symptoms: a comparison between patients undergoing peritoneal dialysis and hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24318806" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12147791" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3443733" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gastrointestinal involvement in insulin-requiring diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3926170" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gastric emptying in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30344804" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gastroparesis in Non-Diabetics: Associated Conditions and Possible Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929141" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Influence of dialysate on gastric emptying time in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428453" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22572613" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mesenteric ischemia in patients with end-stage renal disease: a nationwide longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686664" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mesenteric ischaemia in haemodialysis patients: a case/control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4061501" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mesenteric ischemia in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956804" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Non-occlusive mesenteric ischemia in chronically dialyzed patients: a disease with multiple risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10638582" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Right colonic involvement is associated with severe forms of ischemic colitis and occurs frequently in patients with chronic renal failure requiring hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8258131" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acute abdominal emergencies in patients on long-term ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299146" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nonocclusive mesenteric ischemia: a lethal complication in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25874091" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lanthanum, constipation, bafflying X-rays and a perforated colonic diverticulum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28852493" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gastrointestinal complications induced by sevelamer crystals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23478376" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Improvement of hepatic encephalopathy by application of peritoneal dialysis in a patient with non-end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6766288" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diverticular disease in patients with chronic renal failure due to polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3079996" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Perforation of the colon in renal homograft recipients. A report of 11 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2341002" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diverticular complications of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27684821" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Patients with end-stage renal disease were at an increased risk of hospitalization for acute diverticulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24957670" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Surgery for diverticulitis is associated with high risk of in-hospital mortality and morbidity in older patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9630180" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31180477" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1602518" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Isolated ascending colon ulceration in a patient with chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446520" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Spontaneous perforation of the colon in a hemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3867787" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The gastrointestinal tract in uremic patients on long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088773" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Epidemiology and outcome of acute pancreatitis in end-stage renal disease dialysis patients: a 10-year national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8309363" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pancreatitis in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3530164" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acute pancreatitis in patients with end-stage renal disease without transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2418678" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pancreatitis: an important cause of abdominal symptoms in patients on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673301" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute pancreatitis in peritoneal dialysis and haemodialysis: risk, clinical course, outcome, and possible aetiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18065830" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Frequency and severity of acute pancreatitis in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113429" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acute Pancreatitis in Chronic Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7578505" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcome of pancreatitis in CAPD and HD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10099893" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : On the toxicity of valproic-acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972318" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute pancreatitis during haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25983916" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Two cases of iodixanol-induced pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097488" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk of and Fatality from Acute Pancreatitis in Long-Term Hemodialysis and Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401858" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8159308" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute pancreatitis during CAPD in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193877" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Acute Pancreatitis in Advanced Chronic Kidney Disease and Kidney Transplant Recipients: Results of a US Nationwide Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181382" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute pancreatitis in patients on chronic peritoneal dialysis: an increased risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21084049" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Exocrine pancreatic function in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7817179" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Nephrogenic ascites. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4843196" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Recurrent ascites following peritoneal dialysis. A new syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7873726" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nephrogenic ascites: a poorly understood syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7329495" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A comparison of peritoneal transport in patients with psoriasis and uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157402" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Is nephrogenic ascites related to secondary hyperparathyroidism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12105248" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Strict volume control in the treatment of nephrogenic ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2479308" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Short- and long-term effectiveness, morbidity, and mortality of peritoneovenous shunt inserted to treat massive refractory ascites of nephrogenic origin analysis of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7063919" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hemodynamic improvement after peritoneovenous shunting in nephrogenic ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3300289" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ascites associated with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4433197" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Control of cachexia and ascites in hemodialysis patients by binephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7237868" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hemodialysis ascites in anephric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573025" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Idiopathic dialysis ascites in the nineties: resolution after renal transplantation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
